RAPT Therapeutics, Inc.

RAPTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1673772

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	$1.5M	$3.8M	$5.0M	$5.0M
Research and Development Expense	$101.0M	$67.1M	$57.0M	$45.5M	$34.9M
Operating Expenses	$127.1M	$87.3M	$73.0M	$58.3M	$43.6M
Operating Income (Loss)	-$127.1M	-$85.8M	-$69.2M	-$53.2M	-$43.6M
Nonoperating Income (Expense)	$10.3M	$2.0M	$5.0K	$1.3M	$1.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$116.8M	-$83.8M	-$69.2M	-$51.9M	-$42.3M
Income Tax Expense (Benefit)	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$173.3M	$266.2M	$198.6M	$119.0M	$84.6M
Assets, Current	$161.8M	$252.7M	$193.0M	$115.6M	$80.5M
Cash and Cash Equivalents, at Carrying Value	$47.5M	$38.9M	$24.0M	$24.9M	$77.4M
Liabilities	$26.3M	$21.0M	$12.3M	$14.8M	$11.5M
Liabilities, Current	$21.8M	$14.2M	$9.6M	$11.7M	$9.3M
Accounts Payable, Current	$5.2M	$3.4M	$2.0M	$2.4M	$1.1M
Stockholders' Equity Attributable to Parent	$245.2M	$186.4M	$104.2M	$73.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$97.0M	-$70.8M	-$61.0M	-$40.5M	-$35.5M
Net Cash Provided by (Used in) Investing Activities	$104.1M	-$45.5M	-$81.3M	-$87.4M	-$843.0K
Net Cash Provided by (Used in) Financing Activities	$1.4M	$131.2M	$141.5M	$75.5M	$49.9M
Payments to Acquire Property, Plant, and Equipment	$1.1M	$845.0K	$755.0K	$398.0K	$888.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)